Guidance for Practicing Primary Care

Pros and cons of proposed recommendation for prediabetes and T2D screening


 

The United States Preventive Services Task Force recently released a draft of updated recommendations for screening for prediabetes and type 2 diabetes mellitus (DM). If accepted as written, the new recommendation will be to “screen all asymptomatic adults ages 35 to 70 years who are overweight or obese.” Upon diagnosis of prediabetes, the recommendation is to offer or refer patients to preventive interventions.

Dr. Santina J. G. Wheat, associate professor of family and community medicine at Northwestern University in Chicago

Dr. Santina J.G. Wheat

This new recommendation would replace the one from 2015, which recommended screening adults aged 40-70 who are overweight or obese, lowering the age at which screening begins by 5 years. It would also replace the recommendation of referral to intensive behavioral counseling to promote a healthy diet and exercise.1

The American Diabetes Association (ADA) identifies A1c, fasting plasma glucose, or oral glucose tolerance tests as appropriate tests for the diagnosis of prediabetes and type 2 DM, and the new draft recommendation does not provide a preference for method of screening.2

The USPSTF’s draft recommendation could expand screening with the hope of identifying patients with prediabetes, or those with diabetes who are asymptomatic, with the intent of beginning treatment before there are serious complications.

Unknown diabetes or prediabetes diagnosis common

It has been estimated by the Centers for Disease Control and Prevention that 12% of U.S. adults had DM as of 2015, though nearly 24% were not aware that they had it. Also, according to the CDC, the prevalence of DM increases with age and is higher in those with less than a high school education. The same report indicates that more than 30% of U.S. adults have prediabetes, and with less than 12% of those individuals are aware of it.3 A possible explanation for a patient’s being unaware of a diagnosis could be that it has been documented in a chart but the patient does not know such information is in his or her health record. According to the evidence provided for the updated recommendation, earlier diagnosis may have an important benefit in preventing serious complications.

A modeling study compared simulated screening strategies and found that the most optimal screening strategy from a cost-effectiveness perspective begins between the ages of 30 and 45, with rescreening every 3-5 years. Further models have led researchers to conclude that early diagnosis can lead to decreased cardiovascular events as well as an opportunity for multifactorial treatment.1 For this reason, it makes sense to expand the ages of screening for obese and overweight individuals.

Treatment recommendations are more flexible

The change in treatment recommendations for a new diagnosis of prediabetes is potentially more useful. It may not be feasible or reasonable for physicians to always provide or refer their patients for intensive behavior interventions. The updated recommendation would allow for the inclusion of not only behavioral counseling and health education, but also potential medication options that are currently available but not approved, or that may be available in the future. The evidence review seemed to be mixed in outcome in this area, so the increased flexibility will likely allow for future opportunities.

Pages

Recommended Reading

‘Hidden’ danger of type 2 diabetes diagnosis at early age
MDedge Pediatrics
Another lot of extended-release metformin is recalled in the U.S.
MDedge Pediatrics
Endocrine Society calls for action to reduce insulin costs
MDedge Pediatrics
Pressure builds on CDC to prioritize both diabetes types for vaccine
MDedge Pediatrics
Further warning on SGLT2 inhibitor use and DKA risk in COVID-19
MDedge Pediatrics
Protecting patients with diabetes from impact of COVID-19
MDedge Pediatrics
ASDSA warns of rogue insulin pen use for DIY fillers
MDedge Pediatrics
High obesity rates in Southern states magnify COVID threats
MDedge Pediatrics
Comic books help explain type 1 diabetes to all ages
MDedge Pediatrics
FDA approves new ready-to-inject glucagon product
MDedge Pediatrics